手机版 | 设首页 | 加收藏
当前位置: 网站首页 > 专家 > 专家介绍 > 文章

协和干细胞基因工程有限公司

来源:    作者:    时间:2010-08-03    点击: 次   

    协和细胞基因工程有限公司是中源协和干细胞生物工程股份公司(股票代码600645)与中国医学科学院中国协和医科大学血液学研究所血液病医院共同出资成立的有限责任公司。公司成立于2001年2月,注册在天津新技术产业园区,注册资本金1亿元人民币。

    经过近十年的建设,逐步建成了以协和干细胞基因工程有限公司为运作主体的、我国唯一的、最高等级的干细胞与基因领域产、学、研、用一体化的国家干细胞工程体系。国家干细胞工程体系包括国家干细胞工程产品产业化基地、国家干细胞工程技术研究中心、细胞产品国家工程研究中心、天津脐带血造血干细胞库、天津脐带间充质干细胞库和协和基因库等。

    天津脐带血造血干细胞库是首批经国家卫生部批准设置并通过卫生部执业验收许可的脐带血造血干细胞库,也是首批通过亚洲脐带血库组织验收的脐带血造血干细胞库。目前干细胞库储存量已达16万份,是世界单体储量最大的干细胞库。

    公司通过研发创立了具有独立知识产权的脐带间充质干细胞的体外分离、培养、扩增及应用技术,建设了世界第一个符合国际标准的脐带间充质干细胞库。同时,与多家医院合作开展干细胞治疗研究,已治疗国内、外白血病、肝硬化、帕金森综合症等多种疾病病人数百名,具有很高的有效率。公司累计实现营业收入近12亿元,年平均增长30%以上,累计利税近3亿元。

    公司建立了以来自美国、瑞典、日本、德国、法国等海外留学高层次人员为核心的研发团队,承担了大量国家和天津市课题,取得了近20项有关干细胞和抗体方面的知识产权专利,获国家自然科学和天津市科技进步一、二等奖7项。

    公司的发展得到了各级党委和政府的大力支持,党和国家领导人吴邦国、贾庆林、李长春、曾庆红、吴官正等先后来公司参观考察并给予高度评价。吴邦国委员长参观后强调:“像干细胞技术这样国际领先的项目,我们应该大力发展!”

 

    UNION STEM CELL & GENE ENGINEERING CO., LTD. (USCGEN) was registered in Tianjin Huayuan Hi-tech Park in 2001, with a registration capital of one hundred million RMB and on the basis of technical support from Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College. USCGEN includes the Hematopoietic Stem Cell Bank, the Antibody Department and Tianjin Union Hospital. USCGEN is committed to the cryopreservation and clinical application of stem cells, R&D, manufacture and distribution of monoclonal antibodies and gene chips .
    The Tianjin cord blood stem cell bank established by USCGEN is one of the largest stem cell banks in the world. It is the first approved cord blood stem cell bank in China by both of Ministry of Health, PRC, and AsiaCord, with a preservation capacity of 300 thousand cord blood units. Since April 2001, Tianjin cord blood stem cell bank has searched thousands cord blood units for local and foreigner clients.
    The Antibody Department was established on the basis of technical advantage from the Institute of Hematology, Chinese Academy of Medical Sciences, which has more than 20 years of experience in monoclonal antibody research and development. We have developed more than 60 anti-human monoclonal antibodies clustered by Human leukocyte differentiation antigen (HLDA) workshop with different specificities, and have developed a number of monoclonal antibodies and related kits for flow cytometry. The R&D project “Production of conjugated monoclonal antibody in large scale” was approved by the Ministry of Science and Technology of the People’s Republic of China in 2004. ”The Classification Kit for Anti Erythrocyte Surface IgG\IgM\IgA\C3” was approved by SFDA (State Food and Drug Administration), as well as national key innovational products.
    Stem Cell project is a demonstration project of National Industrial Base of Stem Cell Technology supported by National Development and Reform Commission, as well as key Hi-tech Industrial Project by Tianjin government in 2008.
    Actually, more than 300 staffs work in USCGEN, 95% of them graduated from the university, and 30% hold master and/or doctor degree. Many of them have been trained in the leading universities in the world, or worked as senior manager and researchers in famous companies. USCGEN has established a post-doctoral workstation in 2001.

 

上一篇:上海聚科生物园区有限责任公司简介

下一篇:南京鼓楼医院

  • Cell Stem Cell:核孔蛋白Nup153和Sox2共同调节维持神经前体细胞
    Cell Stem Cell:核孔蛋白Nup153和Sox2共同..
  • 寨卡病毒(ZIKV)给治疗神经胶质母细胞瘤带来希望
    寨卡病毒(ZIKV)给治疗神经胶质母细胞..
  • Nature Protocol:使用新生大鼠作为生物反应器可获得成熟人心肌细胞
    Nature Protocol:使用新生大鼠作为生物反..
  • 美国FDA首次批准基因修饰的免疫T细胞用于癌症治疗
    美国FDA首次批准基因修饰的免疫T细胞用..
  • 美国患者利用自体脂肪干细胞修复腕关节
    美国患者利用自体脂肪干细胞修复腕关节
  • 1
  • 2
  • 3
  • 4
  • 5
关注微信
关注微博


友情链接: 同济大学医学院 生物谷 同济大学

沪ICP备17012695号-2  |  本站内容争议,合作投稿等请联系:admin@chinastemcell.org  
                                                                  Copyright(C) 科技部973重大基础研究《干细胞资源库与干细胞关键技术平台建设》和 华东干细胞库